The FDA does not have to listen to the panels advice
Darsalia, V
BardoxoloneReata Bardoxolone is an activator of nuclear factor erythroid-related factor 2 (Nrf2)
30 gauge needles 30G is one of the most popular gauges for compounded GLP-1 injections
For patients taking Rybelsus, realistic expectations include: Modest weight loss : Typically 35% of baseline body weight over 612 months Gradual progression : Weight loss occurs slowly, not rapidly Individual variation : Some patients may lose more or less than average Plateau effect : Weight loss often slows or stabilises after several months Patient safety considerations are paramount: Common side effects include nausea, vomiting, diarrhoea, and abdominal discomfort, particularly during dose escalation Rare but serious risks include pancreatitis and gallbladder disease [1] [4] If you experience severe, persistent abdominal pain (possibly radiating to the back), stop taking Rybelsus and seek urgent medical attention as this could indicate pancreatitis Regular monitoring of HbA1c, renal function, and body weight is recommended Increased risk of hypoglycaemia when used with insulin or sulfonylureas

Recently, Ozempic has garnered attention for its potential benefits in weight management, even for individuals without diabetes